University of Maryland School of Medicine
Welcome,         Profile    Billing    Logout  
 157 Trials 
301 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mehta, Minesh P
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery with or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC).

Completed
3
298
Europe, Canada, US, RoW
NovoTTF-200M device, Best Standard of Care
NovoCure GmbH
Brain Metastases from Non-small Cell Lung Cancer (NSCLC)
11/24
11/24
NCT04466683: Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia

Active, not recruiting
2
37
US, RoW
Low dose radiation 35 cGy, High dose radiation 100 cGy
Ohio State University Comprehensive Cancer Center, Varian Medical Systems
Covid-19, Sars-CoV2, Pneumonia
12/24
12/25
NCT02847559: Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

Recruiting
2
27
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Electric Field Therapy, NovoTTF-200A Device, NovoTTF-200A, NovoTTF-200A System, NovoTTFields, NovoTumor Treatment Fields, Optune, Optune Device, Quality-of-Life Assessment, Quality of Life Assessment
Northwestern University, NovoCure Ltd., National Cancer Institute (NCI)
Anaplastic (Malignant) Meningioma, Atypical Meningioma, Grade II Meningioma, Grade III Meningioma, Recurrent Meningioma, Supratentorial Meningioma
09/26
12/26
Edelman, Martin J
RAMP-202, NCT04620330 / 2020-004265-39: A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Checkmark Trial initiated for LGSOC and KRAS mutated NSCLC
Dec 2020 - Dec 2020: Trial initiated for LGSOC and KRAS mutated NSCLC
Completed
2
90
Europe, US
avutometinib (VS-6766), avutometinib (VS-6766) and Defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc.
Non Small Cell Lung Cancer, KRAS Activating Mutation
08/23
12/23
NCT03391778 / 2018-004888-31: Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Recruiting
1
250
Europe, Canada, US, RoW
ADP adoptive cell therapy
Adaptimmune
Neoplasms
04/32
04/32
NCT06222242: mychoiceTM Implementation With Medical Oncology Patients

Recruiting
N/A
200
US
mychoiceTM
Fox Chase Cancer Center, Genentech, Inc.
Cancer
06/25
06/25
Harrop, James S
3STLIF, NCT04823858: 3Spine Lumbar Fusion Real World Evidence Study

Recruiting
N/A
200
US
Lumbar Interbody Fusion
3Spine, MCRA
Lumbar Spine Degeneration
05/24
08/26
Halloran, Philip
NCT05837663: Trifecta-Lung cfDNA-MMDx Study

Recruiting
N/A
600
Europe, Canada, US, RoW
University of Alberta, Natera, Inc., One Lambda
Lung Transplantation
11/26
12/27
NCT04239703: Trifecta-Kidney cfDNA-MMDx Study

Recruiting
N/A
300
Europe, Canada, US, RoW
MMDx, Prospera, transplant patient blood sample, HLA antibody
University of Alberta, Natera, Inc., One Lambda
Kidney Transplant Rejection
12/25
12/26
NCT04707872: Trifecta-Heart cfDNA-MMDx Study

Recruiting
N/A
300
Europe, Canada, US, RoW
MMDx diagnostic test, Prospera, HLA antibody
University of Alberta, Natera, Inc., One Lambda
Heart Transplant Rejection
12/26
07/27
Rolfo, Christian
NCT05119933: A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation

Recruiting
1/2
55
US
YL-15293
Shanghai YingLi Pharmaceutical Co. Ltd., Yingli Pharma US, Inc
Advanced Solid Tumor
06/23
12/23
LIBRETTO-001, NCT03157128 / 2017-000800-59: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

Hourglass Jan 2022 - Dec 2022 : Submission for lung cancer
Hourglass Apr 2022 - Dec 2022 : Approval in China for RET+NSCLC, medullary thyroid cancer and thyroid cancer
Checkmark From LIBRETTO-001 trial in RET fusion-positive NSCLC
Aug 2020 - Aug 2020: From LIBRETTO-001 trial in RET fusion-positive NSCLC
Checkmark Granted for advanced RET fusion+ve 2L thyroid cancer [LIBRETTO-001]
More
Active, not recruiting
1/2
856
Europe, Canada, Japan, US, RoW
LOXO-292, Selpercatinib, LY3527723
Loxo Oncology, Inc., Eli Lilly and Company
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
02/25
02/26
Anderson, Karen O
PIVOT-HD, NCT05358717 / 2021-003852-18: A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)

Active, not recruiting
2
252
Europe, Canada, US, RoW
PTC518, Placebo
PTC Therapeutics, PTC Therapeutics, Inc.
Huntington Disease
02/25
08/25
Cross, Raymond K
PROF, NCT05938465: Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects with an IPAA

Recruiting
1/2
50
US
EXE-346, Placebo
Exegi Pharma, LLC, The Emmes Company, LLC
Ileal Pouch
05/26
06/26
MONITOR, NCT06750731: Study of Efficacy and Adherence to Subcutaneous Vs. Intravenous Vedolizumab in Patients with Inflammatory Bowel Disease Using a Novel Remote ing Intervention

Not yet recruiting
N/A
200
US
Tappt
Mercy Medical Center, Takeda
Inflammatory Bowel Disease (IBD), Crohn's Disease, Ulcerative Colitis
09/26
09/26
Griffith, Bartley
BOSTON-2, NCT03656926 / 2018-003205-25: Efficacy + Safety of Liposome Cyclosporine a to Treat Bronchiolitis Obliterans Post Single Lung Transplant

Completed
3
220
Europe, US, RoW
Liposomal Cyclosporine A, L-CsA, Standard of Care, SoC
Zambon SpA, BREATH Therapeutics Inc.
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
03/24
03/24
BOSTON-1, NCT03657342 / 2018-003204-39: Efficacy + Safety of Liposome Cyclosporine a to Treat Bronchiolitis Obliterans Post Single Lung Transplant

Completed
3
220
Europe, US, RoW
Liposomal Cyclosporine A, L-CsA, standard of care, SoC
Zambon SpA, BREATH Therapeutics Inc.
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
04/24
04/24
Shanholtz, Carl
RECOVER, NCT04629105: Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B

Active, not recruiting
1
70
US
Longeveron Mesenchymal Stem Cells (LMSCs), Placebo
Longeveron Inc.
ARDS, Human, Covid19
06/24
07/25
Gammie, James S
ICE-AFIB, NCT03732794: AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment

Active, not recruiting
N/A
150
US
AtriCure CryoICE & AtriClip LAA Exclusion
AtriCure, Inc.
Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation
06/24
06/26
APOLLO, NCT03242642: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Recruiting
N/A
1056
Europe, Canada, US
Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Medtronic Cardiovascular
Mitral Valve Regurgitation
10/26
09/36
Harrison, Daniel
NCT03396822: Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis

Completed
N/A
24
US
Gadoteridol
University of Maryland, Baltimore, Genentech, Inc.
Multiple Sclerosis
05/23
05/23
Shetty, Kirti
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Recruiting
3
160
Europe, Canada, US, RoW
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride
Takeda, Takeda Development Center Americas, Inc.
Alpha1-Antitrypsin Deficiency
03/27
03/29
ARGON-2, NCT04378010 / 2019-003876-38: A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

Terminated
2b
98
Europe, Canada, US, RoW
EDP-305 1.5 mg, EDP-305, EDP-305 2 mg, Placebo
Enanta Pharmaceuticals, Inc, Enanta Pharmaceuticals, Inc.
Non-Alcoholic Steatohepatitis
10/21
11/21
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects

Recruiting
2
240
US, RoW
HM15211, Placebo of HM15211
Hanmi Pharmaceutical Company Limited
NASH - Nonalcoholic Steatohepatitis
05/26
11/26
NCT03878550: Case-Control Study of the Glycotest™ HCC Panel vs AFP for the Detection of Early-stage Hepatocellular Carcinoma

Active, not recruiting
N/A
766
US, RoW
Glycotest, Inc.
Carcinoma, Hepatocellular, Cirrhosis, Liver
08/23
12/24
Hershey, Andrew
NCT04088071: Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation

Recruiting
N/A
15000
US
Catheter ablation
Heart Rhythm Clinical and Research Solutions, LLC, Biosense Webster, Inc.
Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
12/27
12/27
Himelhoch, Seth S
NCT05011903: Integrative Alcohol and Risky Sex Feedback for College Students

Not yet recruiting
N/A
600
US
Cross-tailored Dynamic Feedback, Personalized Feedback Intervention, Dynamic Feedback on General Health Behaviors
Anne E Ray, University of North Texas Health Science Center, Klein Buendel, Inc., National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol Drinking in College, Sexual Behavior
01/27
01/27
Weir, Matthew R
PREFERRED-1, NCT05096195: PRevEnting FracturEs in REnal Disease 1

Active, not recruiting
4
60
Canada
Denosumab 60 mg/ml, Prolia, Calcium and vitamin D prophylaxis, Monitoring of post-injection calcium and phosphate
Western University, Canada, ICES, Academic Medical Organization of Southwestern Ontario, Western University, The Kidney Foundation of Canada
Kidney Diseases, Dialysis; Complications, Fragility Fracture, Chronic Kidney Disease-Mineral and Bone Disorder
12/25
12/25
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
NCT04658017: GARNETâ„¢ Filter (GARNET Device) IDE Used in Chronic Hemodialysis Patients With a Bloodstream Infection

Recruiting
N/A
15
US
GARNET device
Boa Biomedical, Inc., Avania
Bloodstream Infection
10/21
12/21
Levitsky, Josh
NCT01846663: Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

Terminated
4
6
US
Placebo, Rifaximin, XIFAXAN® Tablets
Bausch Health Americas, Inc.
Hepatic Encephalopathy
02/16
02/16
NCT05569759: A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)

Active, not recruiting
2
24
US
zetomipzomib, KZR-616, placebo, sterile water for injection, zetomipzomib in open-label extension
Kezar Life Sciences, Inc.
Autoimmune Hepatitis
02/25
08/25
Bromberg, Jonathan
NCT04803006: A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)

Recruiting
2
18
US
TCD601
ITB-Med LLC
Kidney Transplantation
07/27
07/30
NCT04239703: Trifecta-Kidney cfDNA-MMDx Study

Recruiting
N/A
300
Europe, Canada, US, RoW
MMDx, Prospera, transplant patient blood sample, HLA antibody
University of Alberta, Natera, Inc., One Lambda
Kidney Transplant Rejection
12/25
12/26
KOAR, NCT03326076: Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry

Active, not recruiting
N/A
4000
US
Donor-derived cell-free DNA (AlloSure®), Standard care, Peripheral blood gene expression profiling (AlloMap Kidney), Analytic platform (IBox)
CareDx
Kidney Transplant Rejection
06/25
12/25
ProActive, NCT04091984: The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry

Active, not recruiting
N/A
5000
US
Prospera
Natera, Inc., University of Maryland
Kidney Transplant Rejection
10/26
10/27
Troum, Orrin M
NCT04511702: Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate

Completed
4
191
US
Pegloticase with MTX, Methotrexate
Amgen
Chronic Uncontrolled Gout, Gout, Uncontrolled Gout
01/24
03/24
REPLENISH, NCT05767034: Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)

Active, not recruiting
3
381
Europe, Canada, Japan, US, RoW
Secukinumab 300 mg, AIN457, Secukinumab 150 mg, Placebo to secukinumab
Novartis Pharmaceuticals
Polymyalgia Rheumatica
09/25
02/26
ReLATE, NCT05845593: Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE

Recruiting
N/A
200
US
Decision Support Test
Ampel BioSolutions, LLC
Lupus Erythematosus, Systemic
12/24
03/25
Hardy, Nancy M
E-CELERATE, NCT05181540: A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

Terminated
3
130
US
AB-205, E-CEL cells, Placebo
Angiocrine Bioscience, California Institute for Regenerative Medicine (CIRM)
Hodgkin Lymphoma, Non Hodgkin Lymphoma
12/23
01/25
DALY II USA, NCT04792489: / MB-CART2019.1 for DLBCL

Recruiting
2
110
US
zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine, Bendamustine
Miltenyi Biomedicine GmbH
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Lymphoma, Central Nervous System Lymphoma
12/24
12/26
ELiPSE-1, NCT05336409: A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

Recruiting
1
75
US
CNTY-101, IL-2, Lymphodepleting Chemotherapy
Century Therapeutics, Inc.
R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma
08/25
08/27
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available
N/A
Canada, US, RoW
CTL019, tisagenlecleucel, Kymriah
Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
 
 
NCT06116110: Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

Not yet recruiting
N/A
150
US
Long-term Follow-Up
Miltenyi Biomedicine GmbH
Non Hodgkin Lymphoma
12/39
12/39
NCT05768269: A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product

Recruiting
N/A
375
US
No Intervention
Century Therapeutics, Inc.
Hematological Malignancy, Solid Tumor Malignancy
03/40
03/40
Zandberg, Dan P
NCT02777385: Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer

Completed
2
80
US
Pembrolizumab, Keytruda, Cisplatin, Platinol, IMRT
Dan Zandberg, Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma
04/23
05/23
NCT02289209: Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck

Active, not recruiting
2
51
US
Reirradiation, MK-3475, Keytruda, pembrolizumab
Dan Zandberg, Merck Sharp & Dohme LLC
Recurrent Head and Neck Cancer, Carcinoma, Squamous Cell of Head and Neck
08/23
08/24
CA224-056, NCT04080804: Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Recruiting
2
80
US
Nivolumab, anti-PD-1 antibody, OPDIVO®, Relatlimab, anti-LAG3 antibody, BMS-986016, Ipilimumab, anti-CTLA4 antibody, Yervoy ®
Dan Zandberg, Bristol-Myers Squibb
Head and Neck Squamous Cell Carcinoma (HNSCC)
05/26
09/26
NCT05743270: Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

Withdrawn
2
130
Europe, US, RoW
RP3, CCRT(concurrent chemoradiation therapy), carboplatin and paclitaxel, nivolumab
Replimune Inc., Bristol-Myers Squibb
Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
03/26
06/26
NCT04369937: HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma

Active, not recruiting
2
18
US
IMRT (Intensity Modulated Radiotherapy), Pembrolizumab, Cisplatin, ISA101b, HPV-16 Vaccine
Dan Zandberg, Merck Sharp & Dohme LLC, ISA Pharmaceuticals
HPV-Related Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
06/25
06/26
NCT04326257: Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Active, not recruiting
2
20
US
Nivolumab+Relatlimab, Nivolumab: OPDIVO/ BMS-936558/ MDX1106/ ONO-4538;, Relatlimab: BMS-986016, Nivolumab+Ipilimumab, Nivolumab: OPDIVO/ BMS-936558/ MDX1106/ ONO-4538, Ipilimumab: YERVOY/ BMS-734016/ MDX-010
Dan Zandberg, Bristol-Myers Squibb
Squamous Cell Carcinoma of the Head and Neck
08/23
08/24
KEYNOTE F92, NCT05597839: Study of DF9001 in Patients With Advanced Solid Tumors

Recruiting
1/2
242
US
DF9001, pembrolizumab, KEYTRUDA®
Dragonfly Therapeutics, Merck Sharp & Dohme LLC
Solid Tumor, Adult
08/25
11/27
KURRENT-HN, NCT04997902: Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Recruiting
1/2
40
US
Tipifarnib, Alpelisib, BYL719
Kura Oncology, Inc.
HNSCC
07/25
07/25
NCT05472506: Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer

Withdrawn
1
54
US
IK-175 + nivolumab
Ikena Oncology, Bristol-Myers Squibb
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Head Cancer, Neck Cancer, Head Cancer Neck, Neck Carcinoma
04/23
04/23
Kim, Esther
E-CELERATE, NCT05181540: A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

Terminated
3
130
US
AB-205, E-CEL cells, Placebo
Angiocrine Bioscience, California Institute for Regenerative Medicine (CIRM)
Hodgkin Lymphoma, Non Hodgkin Lymphoma
12/23
01/25
HIBISCUS, NCT04624659 / 2020-003884-25: A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease

Recruiting
2/3
344
Europe, Canada, US, RoW
Etavopivat Tablets Low dose, FT-4202, Etavopivat Tablets High dose, Placebo Tablets, placebo, Etavopivat Tablets
Forma Therapeutics, Inc., Novo Nordisk A/S
Sickle Cell Disease
03/26
04/27
DARE, NCT04567420: DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer

Recruiting
2
70
US
Palbociclib, IBRANCE, Fulvestrant, Faslodex, Adjuvant Therapy, Standard of Care
Criterium, Inc.
Breast Cancer
12/27
12/27
Simone, Charles
NCT04716946: Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

Recruiting
2
40
US
Durvalumab, Stereotactic Body Radiation Therapy, SBRT
Memorial Sloan Kettering Cancer Center, AstraZeneca
NSCLC, Non-small Cell Lung Cancer, Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IIIA, PD-L1 Gene Mutation
02/26
02/26
Baliga, Rajendra
NCT04239703: Trifecta-Kidney cfDNA-MMDx Study

Recruiting
N/A
300
Europe, Canada, US, RoW
MMDx, Prospera, transplant patient blood sample, HLA antibody
University of Alberta, Natera, Inc., One Lambda
Kidney Transplant Rejection
12/25
12/26
Wilkerson, Gentry
NCT05228834: Voxelotor Neurocognitive Function Study

Terminated
3
1
US
Voxelotor Only Product in Oral Dose Form, Placebo
Pfizer
Sickle Cell Disease
09/22
09/22
NCT03956277: Single-center, Feasibility Study to Evaluate the Use and Safety of the Percutaneous Ultrasound Gastrostomy Technique

Active, not recruiting
N/A
40
US
PUG
CoapTech, University of Maryland, Baltimore, University of Maryland, Baltimore Washington Medical Center
Gastrostomy
10/23
02/24
Christenson, Robert H
NCT05422131: Clozapine Therapy Sample Collection - Method Comparison Study

Completed
N/A
153
US
MyCare Insite Clozapine Test
Saladax Biomedical, Inc., The Feinstein Institutes for Medical Research, University of Maryland, Baltimore
Patients Prescribed Clozapine
01/23
05/23
NCT06053593: Ketostix® and Keto-Diastix® Performance Study

Completed
N/A
126
US
Testing of self collected urine, Labeling Evaluation, Urine Control testing
Ascensia Diabetes Care
Urinalysis
11/23
11/23
Nguyen, Vinh
ReLATE, NCT05845593: Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE

Recruiting
N/A
200
US
Decision Support Test
Ampel BioSolutions, LLC
Lupus Erythematosus, Systemic
12/24
03/25
Fisher, Stacy
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/25
12/25
Lyke, Kirsten E
NCT05604521: A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI

Terminated
1
31
US
PfSPZ Vaccine, PfSPZ Challenge (7G8), Normal Saline, Placebo
Sanaria Inc., University of Maryland, Baltimore, National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Malaria,Falciparum
09/23
09/23
Seliger, Stephen
FALCON, NCT03918447 / 2018-004651-20: A Trial of Bardoxolone Methyl in Patients With ADPKD -

Terminated
3
667
Europe, Japan, US, RoW
Bardoxolone methyl oral capsule, RTA 402, Placebo oral capsule
Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc., REATA PHARMACEUTICALS, INC
Autosomal Dominant Polycystic Kidney, ADPKD
08/23
08/23
Badiyan, Shahed
NCT04162665: Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer

Terminated
2
4
US
Adaptive short course radiation therapy, Standard of care chemotherapy regimen
Washington University School of Medicine, Viewray Inc.
Gastric Adenocarcinoma
12/23
11/24
NCT04331041: Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma

Recruiting
2
42
US
Adaptive stereotactic body radiation therapy, Adaptive SBRT, Defactinib, VS-6063, PF-04554878, Tumor biopsy, Research blood draw
Washington University School of Medicine, National Cancer Institute (NCI), Verastem, Inc.
Pancreas Cancer, Cancer of the Pancreas, Pancreas Adenocarcinoma
06/27
06/28
ARTIA-Pancreas, NCT05764720: Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach

Recruiting
N/A
134
US
Daily Adaptive External Beam Radiation Therapy
Varian, a Siemens Healthineers Company, Washington University School of Medicine
Pancreatic Cancer
02/26
02/28
Timofte, Irina L
LAMBDA 002, NCT05170425: (Lung Registry) Study

Active, not recruiting
N/A
154
US
Prospera
Natera, Inc.
Lung Transplant Rejection
08/26
05/27
Kemmer, Nyingi
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
FRESH, NCT05639543 / 2022-001639-10: FXR Effect on Severe Alcohol-Associated Hepatitis () Study

Recruiting
2
50
Europe, US
INT-787, Placebo
Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc.
Alcohol Associated Hepatitis
12/24
03/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
NCT06685692: A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)

Recruiting
2
10
US
ADX-629
Aldeyra Therapeutics, Inc.
Alcohol Hepatitis
12/25
12/25
Yared, Jean
ALLELE, NCT03394365 / 2017-002949-30: Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

Checkmark Data from ALLELE trial for post-transplant lymphoproliferative disease
Dec 2021 - Dec 2021: Data from ALLELE trial for post-transplant lymphoproliferative disease
Recruiting
3
66
Europe, Canada, US, RoW
tabelecleucel, tab-cel®, ATA129, EBV-CTL
Atara Biotherapeutics
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
08/25
06/27
NCT03133221: 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation

Active, not recruiting
2
17
US
Zydelig, Idelalisib
University of Maryland, Baltimore, Gilead Sciences, University of Miami Sylvester Comprehensive Cancer Center
Non Hodgkin Lymphoma, Follicular Lymphoma, Indolent Lymphoma, B-cell Lymphoma, Transformed Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma
06/23
03/25
FIRCE-1, NCT05972720: A Phase 2 Study of Firi-cel in Patients with Relapsed/refractory Large B-cell Lymphoma

Recruiting
2
123
US
Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
CARGO Therapeutics
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
09/25
12/26
EBVision, NCT04554914 / 2020-000177-25: A Study to Evaluate Tabelecleucel in Participants with Epstein-barr Virus-associated Diseases

Hourglass Jan 2023 - Dec 2023 : From P2 trial for Epstein-Barr virus-associated sarcoma
Recruiting
2
190
Europe, US
Tabelecleucel, tab-cel®, ATA129, EBV-CTLs
Atara Biotherapeutics
Epstein-Barr Virus (EBV)-associated Diseases, EBV+ Lymphoproliferative Disease with Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease with Acquired (non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma
06/27
05/29
FELIX, NCT04404660: A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Hourglass Jul 2024 - Dec 2024 : Submission in UK for adult r/r B-ALL
Active, not recruiting
1/2
153
NA
AUTO1, Obecabtagene autoleucel (obe-cel)
Autolus Limited
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
05/25
05/25
PBCAR0191-01, NCT03666000: Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and R/r B-cell ALL

Recruiting
1
129
US, RoW
Azer-cel, Allogeneic Anti-CD19 CAR T cells, PBCAR0191, Fludarabine, Cyclophosphamide, IL-2, Bendamustine
Imugene Limited
Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
06/25
06/27
Blondin, Nicholas
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Calendar Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
01/26
01/28
NCT05226494: Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma

Recruiting
1
34
US
fb-PMT, NP-100, NP751
NanoPharmaceuticals LLC
Glioma, Malignant
10/24
10/25
NCT04656535: AB154 Combined with AB122 for Recurrent Glioblastoma

Recruiting
1
46
US
Zimberelimab, Domvanalimab, Placebo
Yale University, National Cancer Institute (NCI), Arcus Biosciences, Inc.
Glioblastoma
02/25
12/25
Kottilil, Shyamasundaran
NCT06063330: Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects

Completed
1
66
US
RQ-001, Placebo
Red Queen Therapeutics, Inc., PPD
COVID-19, Infectious Disease, Symptomatic COVID-19 Infection Laboratory-Confirmed, SARS CoV 2 Infection
01/24
01/24
Weir, Matt
NCT04239703: Trifecta-Kidney cfDNA-MMDx Study

Recruiting
N/A
300
Europe, Canada, US, RoW
MMDx, Prospera, transplant patient blood sample, HLA antibody
University of Alberta, Natera, Inc., One Lambda
Kidney Transplant Rejection
12/25
12/26
Smith, Nancy
ENABLAR-2, NCT05065411: Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

Terminated
3
5
US
Enobosarm & Abemaciclib Combo, VERU-024, Verzenio, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant, exemestane, fulvestrant, exemestane plus everolimus
Veru Inc.
Metastatic Breast Cancer
10/23
01/24
HIBISCUS, NCT04624659 / 2020-003884-25: A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease

Recruiting
2/3
344
Europe, Canada, US, RoW
Etavopivat Tablets Low dose, FT-4202, Etavopivat Tablets High dose, Placebo Tablets, placebo, Etavopivat Tablets
Forma Therapeutics, Inc., Novo Nordisk A/S
Sickle Cell Disease
03/26
04/27
KICKSTART, NCT04622007: Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC

Hourglass Jan 2024 - Mar 2024 : Q1'24 - Data from P2b KICKSTARTtrial in combination with Keytruda for PD-L1+ve 1L NSCLC
Active, not recruiting
2
68
US, RoW
Tomivosertib, eFT508, Pembrolizumab, Keytruda®, Pemetrexed, Alimta®
Effector Therapeutics, Medpace, Inc., ICON plc
Non-small Cell Lung Cancer
10/24
12/24
BTX-BCI-016-PRT, NCT04875351: Breast Cancer Index (BCI) Registry

Active, not recruiting
N/A
3465
US
Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test, Breast Cancer Index (BCI) Test
Biotheranostics, Inc.
Breast Cancer
12/28
12/28
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting
N/A
30000
Europe, Canada, US, RoW
MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint
Agendia
Breast Cancer
04/37
12/37
Young, Cindi
SPRAY-CB, NCT03893370: RejuvenAir® System Trial for COPD With Chronic Bronchitis

Active, not recruiting
N/A
210
Europe, US
RejuvenAir System, Sham Control Procedure
CSA Medical, Inc.
Chronic Bronchitis
05/25
09/26
Beach, Dana
NCT05228834: Voxelotor Neurocognitive Function Study

Terminated
3
1
US
Voxelotor Only Product in Oral Dose Form, Placebo
Pfizer
Sickle Cell Disease
09/22
09/22
KOURAGE, NCT06374797: A Study of Auxora in Patients with AKI and Injurious Lung "Crosstalk"

Recruiting
2
150
US
Auxora, Placebo
CalciMedica, Inc.
Acute Kidney Injury
08/25
08/25
Eggleston, Caitlin M
KNIGHTS, NCT06212583: High-Risk Metachronous Oligometastatic Prostate Cancer Trial

Recruiting
2
88
US
niraparib/abiraterone acetate, Stereotactic ablative radiation therapy (SABR), Androgen deprivation therapy (ADT)
University of Maryland, Baltimore, Janssen Scientific Affairs, LLC
Prostate Cancer, Oligometastatic Disease
12/28
12/29
NCT06187103: Evaluation of Improved Onboard Patient Imaging

Recruiting
N/A
40
US
HyperSight Imaging
Varian, a Siemens Healthineers Company
Head and Neck Cancer, Breast Cancer, Upper Gastrointestinal Cancer, Lung Cancer, Pelvic Cancer
06/25
06/25
Diggs, Charalett
NCT05521191: A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease

Recruiting
1
70
US
RGLS8429, Placebo
Regulus Therapeutics Inc.
Autosomal Dominant Polycystic Kidney Disease, ADPKD, Polycystic Kidney, Autosomal Dominant
04/25
06/25
Bartosic, Amanda
KOAR, NCT03326076: Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry

Active, not recruiting
N/A
4000
US
Donor-derived cell-free DNA (AlloSure®), Standard care, Peripheral blood gene expression profiling (AlloMap Kidney), Analytic platform (IBox)
CareDx
Kidney Transplant Rejection
06/25
12/25
 

Download Options